No Data
No Data
Bullish Outlook on Werewolf Therapeutics: Unveiling the Potential of WTX-124 as a Best-in-Class IL-2 Therapy
BofA Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $10
BofA Securities analyst Jason Zemansky maintains $Werewolf Therapeutics(HOWL.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of
JMP Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $12
JMP Securities analyst Reni Benjamin maintains $Werewolf Therapeutics(HOWL.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 3
Werewolf Therapeutics Says Initial Data Show Potential Non-Hodgkin Lymphoma Treatment Increased Therapeutic Window in Phase 1 Clinical Trial
Werewolf Therapeutics (HOWL) said Tuesday that initial results showed that potential non-Hodgkin lymphoma treatment WTX-330 increased therapeutic window in a phase 1 clinical trial. The company also s
Express News | Werewolf Therapeutics Announced Initial Results From Phase 1 Trial Of WTX-330 As Monotherapy For Immunotherapy Insensitive Or Resistant Locally Advanced Or Metastatic Solid Tumors Or Non-Hodgkin Lymphoma, Additional Results Expected In Q4 Of 2024
Express News | Werewolf Therapeutics: Results Showed Encouraging Signals of Clinical Activity
No Data